Beta Bionics, Inc. (BBNX) Stock

About Beta Bionics, Inc.

Beta Bionics, Inc. is led by CEO Sean T. Saint, employs 352 people, headquartered in US, publicly traded since 2025.

Beta Bionics, Inc. (BBNX) stock trades at $19.16 with a market capitalization of $862.00M. The stock is valued at a negative price-to-earnings (P/E) ratio of -11.29, reflecting a net loss over the last twelve months, price-to-book of 3.29, price-to-sales of 7.17. Over the past 52 weeks the stock has ranged between $8.80 and $32.71, and currently trades 41.4% below its 52-week high.

On profitability, Beta Bionics, Inc. generates a return on equity (ROE) of -26.30% (negative, reflecting a net loss), return on capital employed of -31.17%, an operating margin of -72.00%, a net profit margin of -61.32%.

Beta Bionics, Inc. by the numbers, 2022–2025

Between 2022 and 2025 Beta Bionics, Inc. reported revenue of $0 rising to $100.0M. Compounded, revenue has grown —% a year over five years, —% over three, 53.9% over the last twelve months. Net profit fell to $-73.0M.

Operating margin went from -36784.4% in 2022 to -71.5% in 2025, a gain of 36712.9 percentage points. The most recent net margin is -61.32%. On a trailing twelve-month basis to Jun '26, revenue is $119.0M and net profit $-72.0M.

Borrowings rose from $4.0M to $7.0M, cash from operations was $-51.0M in the latest year, positive in 0 of the last 4.

Return on equity has averaged -33.5% over five years, and was -25.4% in the most recent year.

The share price itself has compounded at —% a year over five years, —% over three, —% over the last year. Past price movement is history, not a forecast.

Figures are as reported and in the company's own reporting currency. They describe what has already happened and carry no implication about what follows.

Beta Bionics, Inc. (BBNX) — frequently asked questions